Q2 Earnings Estimate for Flora Growth Issued By Roth Capital

Flora Growth Corp. (NASDAQ:FLGC) – Stock analysts at Roth Capital lowered their Q2 2025 earnings estimates for shares of Flora Growth in a report issued on Friday, November 15th. Roth Capital analyst W. Kirk now anticipates that the company will post earnings per share of $0.02 for the quarter, down from their prior forecast of $0.07. The consensus estimate for Flora Growth’s current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.

Separately, Alliance Global Partners restated a “neutral” rating on shares of Flora Growth in a research report on Thursday, August 15th.

Flora Growth Stock Up 2.6 %

Shares of Flora Growth stock opened at $1.20 on Monday. Flora Growth has a 1-year low of $0.70 and a 1-year high of $2.93. The firm’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $1.23. The company has a quick ratio of 0.79, a current ratio of 1.02 and a debt-to-equity ratio of 0.43.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Flora Growth stock. Renaissance Technologies LLC lifted its stake in shares of Flora Growth Corp. (NASDAQ:FLGC) by 105.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,595 shares of the company’s stock after purchasing an additional 81,982 shares during the period. Renaissance Technologies LLC owned approximately 1.19% of Flora Growth worth $163,000 at the end of the most recent reporting period. 36.01% of the stock is currently owned by institutional investors and hedge funds.

Flora Growth Company Profile

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.